Outcomes for patients implanted with a cardioverter-defibrillator at <19 years of age: a Swedish national study

瑞典一项全国性研究:19岁以下植入心脏复律除颤器患者的预后

阅读:1

Abstract

AIMS: To explore the prevalence and incidence of paediatric implantable cardioverter-defibrillator (ICD) patients in Sweden and identify risk factors associated with appropriate shocks and adverse events. METHODS AND RESULTS: We performed a nationwide, retrospective cohort study of ICD use in paediatric patients (<19 years) between 1995 and 2017; 120 patients underwent ICD implantation at median age 14.7 (range 1.1-18.9) years and were followed for 7.1 (0.3-20.4) years. Fifty-four patients (45%) received a primary preventive ICD; 46% had cardiomyopathy, and 41% had primary electrical disease. The estimated 5-year survival without appropriate shocks was 68% (confidence interval 59-78). Secondary preventive ICDs and lower weight (<30 kg) at implantation were associated with a higher rate of appropriate shocks, respectively. Lower weight at implantation was not a risk factor for adverse events. Inadequate medication and insufficient compliance were common in patients who experienced shocks. Less than half (46%) of the cases with inappropriate shocks were adequately medicated with good compliance. Secondly, an incidence and prevalence study of all paediatric and adult patients who had an ICD implanted in Sweden was analysed in 4-year periods between 2002 and 2021. The incidence of paediatric ICD implantations in Sweden peaked at 0.56 per 100 000 person-years in 2010-13, decreasing to 0.45 per 100 000 person-years in the last study period (2018-21). CONCLUSION: Appropriate shocks were more than twice as common in the youngest patient group, whereas adverse events were not more frequent than in the older patient group. Inadequate medication and lack of compliance were common in connection with ICD shocks.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。